Inactive Instrument

Applied Molecular Transport Inc.

AMTI

US03824M1099

Biotechnology & Medical Research

Applied Molecular Transport Inc. Announces Resignation of Randall Mrsny from the Board of Directors

January 04, 2023 at 11:09 am

Applied Molecular Transport Inc. announced that on December 29, 2022, Randall Mrsny, Ph.D., informed the Board of Directors of company that he was resigning from the Board effective on such date.

Latest news about Applied Molecular Transport Inc.

Applied Molecular Transport Inc.(NasdaqCM:AMTI) dropped from NASDAQ Composite Index	12-28	CI
Cyclo Therapeutics, Applied Molecular Transport Complete Merger	12-27	MT
Applied Molecular Transport Inc.(NasdaqCM:AMTI) dropped from S&P TMI Index	12-27	CI
Cyclo Therapeutics, Inc. completed the acquisition of Applied Molecular Transport Inc. from a group of shareholders for $10.2 million.	12-26	CI
Applied Molecular Transport Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-09	CI
Cyclo Therapeutics, Applied Molecular Transport Agree to Merge	21/09/23	MT
North American Morning Briefing : Stock Futures -2-	16/08/23	DJ
Applied Molecular Transport Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	14/08/23	CI
Applied Molecular Transport Inc.(NasdaqGS:AMTI) dropped from Russell 3000E Value Index	23/06/23	CI
Applied Molecular Transport Inc.(NasdaqGS:AMTI) dropped from Russell 3000E Index	23/06/23	CI
Applied Molecular Transport Inc.(NasdaqGS:AMTI) dropped from Russell Microcap Value Index	23/06/23	CI
Applied Molecular Transport Inc.(NasdaqGS:AMTI) dropped from Russell Microcap Index	23/06/23	CI
Declaration of Voting Results by Applied Molecular Transport Inc	15/06/23	CI
Applied Molecular Transport Inc. Announces Executive Changes	08/06/23	CI
Applied Molecular Transport Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	11/05/23	CI
Applied Molecular Transport Inc Receives a Shareholder Proposal from Glenbrook Capital, L.P	28/04/23	CI
Applied Molecular Transport Inc. Approves Workforce Reduction	28/03/23	CI
Chardan Downgrades Applied Molecular Transport to Neutral From Buy, Amid Uncertainty Regarding Clinical Programs and Company Strategy, Withdraws Price Target	28/03/23	MT
Applied Molecular Transport Announces Process to Explore Strategic Alternatives	27/03/23	CI
Applied Molecular Transport Plans to Slash 57% Jobs While 'Exploring Strategic Alternatives'; CEO Tahir Mahmood to Step Down	27/03/23	MT
Applied Molecular Transport Inc. Announces CEO Changes	27/03/23	CI
Applied Molecular Transport Inc. Announces Executive Changes	27/03/23	CI
Applied Molecular Transport Inc. Announces Executive Changes	09/03/23	CI
Applied Molecular Transport Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	09/03/23	CI
Applied Molecular Transport Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	09/03/23	CI

Chart Applied Molecular Transport Inc.

Duration

Period

More charts

Applied Molecular Transport Inc. is a clinical-stage biopharmaceutical company. The Company is leveraging its technology platform to design and develop a pipeline of oral biologic product candidates to treat autoimmune, inflammatory, metabolic, and other diseases. The Company's pipeline includes AMT-101, and AMT-126. AMT-101 is a gastrointestinal-selective oral fusion of interleukin 10 (IL-10) and its proprietary carrier molecule that has been designed for active transport across the intestinal epithelium (IE) barrier into local gastrointestinal (GI) tissue. AMT-126 is a GI-selective oral fusion of interleukin 22 (IL-22) and its proprietary carrier molecule presently in development for diseases related to IE barrier function defects. Its technology platform enables it to design and develop various oral biologic therapeutic modalities, such as peptides, proteins, full-length antibodies, antibody fragments, and ribonucleic acid (RNA) therapeutics with development-stage drugs.

Sector

Biotechnology & Medical Research

Calendar

12/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
MODERNA, INC.	+52.09%	63.85B
IQVIA HOLDINGS INC.	-2.37%	41.83B
LONZA GROUP AG	+40.01%	40.47B
CELLTRION, INC.	-10.22%	27.17B
ICON PUBLIC LIMITED COMPANY	+13.20%	26.52B
ALNYLAM PHARMACEUTICALS, INC.	-21.58%	18.69B
BIO-TECHNE CORPORATION	+2.73%	12.73B
UNITED THERAPEUTICS CORPORATION	+22.07%	12.11B
MEDPACE HOLDINGS, INC.	+27.67%	12.07B

Other Biotechnology & Medical Research